

PTO FAX NO.: 703-308-4242

ATTENTION: Examiner D. Lukton  
Group Art Unit 1653

FAX RECEIVED  
APR 05 2001  
GROUP 1600


**OFFICIAL COMMUNICATION**  
**FOR THE PERSONAL ATTENTION OF**  
**EXAMINER D. Lukton**

**CERTIFICATION OF FACSIMILE TRANSMISSION**

I hereby certify that the following Preliminary Amendment, including 5 pages, in re Application of Green et al., Serial No. 09/506,430, filed February 17, 2000, for PHARMACEUTICAL ANGIOSTATIC DIPEPTIDE COMPOSITIONS AND METHODS OF USE THEREOF is being facsimile transmitted to the Patent and Trademark Office on the date shown below.

Number of pages being transmitted, including this page: 6

Dated: April 5, 2001

  
Dana Kane

***PLEASE CONFIRM RECEIPT OF THIS PAPER BY  
RETURN FACSIMILE AT (415) 576-0300***

TOWNSEND and TOWNSEND and CREW LLP  
Two Embarcadero Center, 8th Floor  
San Francisco, CA 94111-3834  
Telephone: (415) 576-0200/Fax: (415) 576-0300

I hereby certify that this correspondence is being sent by facsimile transmission to:

at Fax No.: 1-703-308-4242

On

TOWNSEND and TOWNSEND and CREW LLP

By:

Supp. Amdt  
10/C  
PATENT  
Attorney Docket No.: 15542-002330US  
Client Reference No.: 121

Linda  
FAX RECEIVED 4/12/01

APR 05 2001

GROUP 1600

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Green *et al.*

Application No.: 09/506,430

Filed: February 17, 2000

For: PHARMACEUTICAL  
ANGIOSTATIC DIPEPTIDE  
COMPOSITIONS AND METHODS OF  
USE THEREOF

Examiner: Lukton, David

Art Unit: 1653

PRELIMINARY AMENDMENT

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

Prior to examination on the merits of the above-referenced application, please enter the following amendments and remarks.

IN THE CLAIMS:

18. (New) A method of inhibiting neovascularization in a subject in need thereof comprising:

administering to said subject a pharmaceutical preparation comprising a pharmaceutically acceptable carrier and an amount of a compound effective to inhibit neovascularization with the formula of R'-Glu-Trip-R'' or pharmaceutically acceptable salts thereof,

wherein R' and R'' is absent or a moiety independently selected from the group consisting of an amide, an imide, an ester, an anhydride, an ether, a methyl-alkyl ester, an ethyl-alkyl ester, an alkyl group, and an aryl group,